Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
PRESERVE-006
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
- NCT05682443 ↗
- Active, not recruiting
- OncoC4, Inc.
- Focused
We haven't built an HCP commentary report on PRESERVE-006 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PRESERVE-006 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ONC-392 low; ONC-392 high; lutetium Lu 177 vipivotide tetraxetan
- Arms
- Arm 1: ONC-392 low dose plus lutetium Lu 177 vipivotide tetraxetan · Experimental
- Arm 2: ONC-392 high dose plus lutetium Lu 177 vipivotide tetraxetan · Experimental
- Arm 3: lutetium Lu 177 vipivotide tetraxetan · Active comparator
- Enrollment
- 148
- Primary outcomes
- DLT (Dose escalation Phase 1)
- PSA50 (Dose Expansion Phase 2)
- rPFS (Dose Expansion Phase 2)
- TEAEs and irAEs (Dose Expansion Phase 2)
- Sponsor
- OncoC4, Inc. with Prostate Cancer Clinical Trials Consortium
- Start
- Dec 11, 2023
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05682443 · updated May 22, 2026